AKAnita Sugam Kale

Anita Sugam Kale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anita Sugam Kale has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Goh

    Paediatric Allergy Service and Respiratory Medicine Service, Department of Paediatrics, KK Women’s and Children’s Hospital, Singapore 229899, Singapore

    1 shared publication
  • Arijit Biswas

    Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Kent Ridge, 119228, Singapore

    1 shared publication
  • Bee Wah Lee

    Department of Paediatrics, Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore

    1 shared publication
  • Chia Yin Chong

    KK Women's and Children's Hospital

    1 shared publication
  • Chin Wee Lai

    Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore & National University Health System, Singapore, Singapore

    1 shared publication
  • Felicia Yeoh

    Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore & National University Health System, Singapore, Singapore

    1 shared publication

Latest Publications

  • Open Access

    Maternal RSV Vaccination and Complementary Infant-Protection Strategies in Singapore: A Modified Nominal Group Technique Consensus Study

    by Chia Yin Chong, Anne Goh, Anita Sugam Kale, Julian Hean Leng Kang, Bee Wah Lee, Manisha Mathur, Shephali Tagore

    Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in infants and a major contributor to infant morbidity and mortality. A previous Singapore consensus addressed RSV disease burden and the role of the monoclonal antibody, nirsevimab, but did not extend to maternal RSV vaccination or its complementary use with long-acting monoclonal antibodies (mAbs). We sought structured expert consensus on positioning maternal RSV vaccination and a complementary prevention strategy in Singapore. Methods: A modified nominal group technique (mNGT) was used. A multidisciplinary panel of seven Singapore-based experts in obstetrics, including maternal–fetal medicine and paediatrics (respiratory, infectious disease, immunisation, and immunology), reviewed a pre-circulated targeted evidence review and four draft statements across four themes (burden, preventive pathways, maternal RSV vaccination, and complementary strategy), with the opportunity to submit written comments in advance. At a live virtual meeting on 16 June 2026, facilitated by a medical communications agency, the panel first discussed the evidence underpinning each draft statement and then voted openly (non-anonymously) on each statement in sequence. Consensus was predefined as ≥70% agreement. Statements that did not reach consensus were refined collectively, with each expert contributing in turn, and re-voted. Results: All seven experts attended and voted. Two statements reached consensus in Round 1 (Theme 2, 7/7; Theme 4, 6/7) and two after a single round of modification (Theme 1, 0/7 and then 7/7 after “first months of life” was specified as “first six months of life”; Theme 3, 3/7 and then 6/7 after “eligible pregnancies” was explicitly defined). The final statements cover RSV burden in the first six months of life, informed choice of preventive pathway, maternal RSV vaccination as an antenatal option for eligible pregnancies, and a complementary strategy in which a long-acting mAb (nirsevimab) is considered for infants not adequately protected by maternal vaccination. Conclusions: This expert consensus supports maternal RSV vaccination as an antenatal prevention option for eligible pregnancies in Singapore and a complementary strategy with nirsevimab for infants not adequately covered by maternal vaccination. The statements represent expert consensus intended to inform, not replace, national guidance.

  • Open Access

    Proteomic analysis of human placental syncytiotrophoblast microvesicles in preeclampsia

    by Sonia Baig, Narasimhan Kothandaraman, Jayapal Manikandan, Li Rong, Kim Huey Ee, Jeffrey Hill, Chin Wee Lai, Wan Yu Tan, Felicia Yeoh, Anita Kale, et al.

    Placental syncytiotrophoblast microvesicles (STBM) are shed into the maternal circulation during normal pregnancy. STBM circulate in significantly increased amounts in preeclampsia (PE) and are considered to be among contributors to the exaggerated proinflammatory, procoagulant state of PE. However, protein composition of STBM in normal pregnancy and PE remains unknown. We therefore sought to determine the protein components of STBM and whether STBM protein expressions differ in preeclamptic and normal pregnancies. Patients with PE (n = 3) and normal pregnant controls (n = 6) were recruited. STBM were prepared from placental explant culture supernatant. STBM proteins were analyzed by a combination of 1D Gel-LC-MS/MS. Protein expressions levels were quantified using spectral counts and validated by immunohistochemistry. Over 400 proteins were identified in the STBM samples. Among these, 25 proteins were found to be differentially expressed in preeclampsia compared to healthy pregnant controls, including integrins, annexins and histones. STBM proteins include those that are implicated in immune response, coagulation, oxidative stress, apoptosis as well as lipid metabolism pathways. Differential protein expressions of STBM suggest their pathophysiological relevance in PE.